CA2832031C - Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same - Google Patents

Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same Download PDF

Info

Publication number
CA2832031C
CA2832031C CA2832031A CA2832031A CA2832031C CA 2832031 C CA2832031 C CA 2832031C CA 2832031 A CA2832031 A CA 2832031A CA 2832031 A CA2832031 A CA 2832031A CA 2832031 C CA2832031 C CA 2832031C
Authority
CA
Canada
Prior art keywords
cell
disease
cancer
measuring
metabolic activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2832031A
Other languages
English (en)
French (fr)
Other versions
CA2832031A1 (en
Inventor
Reuven Tirosh
Fernando Patolsky
Hagit PERETZ-SOROKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CA2832031A1 publication Critical patent/CA2832031A1/en
Application granted granted Critical
Publication of CA2832031C publication Critical patent/CA2832031C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Oncology (AREA)
  • Ecology (AREA)
CA2832031A 2011-04-06 2012-04-04 Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same Active CA2832031C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161472213P 2011-04-06 2011-04-06
US61/472,213 2011-04-06
PCT/IL2012/050125 WO2012137207A1 (en) 2011-04-06 2012-04-04 Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Publications (2)

Publication Number Publication Date
CA2832031A1 CA2832031A1 (en) 2012-10-11
CA2832031C true CA2832031C (en) 2019-09-17

Family

ID=46124593

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2832031A Active CA2832031C (en) 2011-04-06 2012-04-04 Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Country Status (11)

Country Link
US (3) US8728758B2 (https=)
EP (1) EP2694962B1 (https=)
JP (1) JP5990254B2 (https=)
KR (1) KR102010600B1 (https=)
CN (1) CN103518133B (https=)
AU (1) AU2012240953B2 (https=)
BR (1) BR112013025782B1 (https=)
CA (1) CA2832031C (https=)
DK (1) DK2694962T3 (https=)
ES (1) ES2627154T3 (https=)
WO (1) WO2012137207A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832031C (en) 2011-04-06 2019-09-17 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
WO2015057713A1 (en) * 2013-10-14 2015-04-23 Case Western Reserve University Metabolic analyzer for optimizing health and weight management
CN106164286A (zh) 2013-10-22 2016-11-23 拉莫特特拉维夫大学有限公司 用于检测的方法和系统
ITRM20130700A1 (it) * 2013-12-19 2015-06-20 Stichting Katholieke Univ Metodo per il rilevamento di cellule tumorali circolanti
CN105303035A (zh) * 2015-09-29 2016-02-03 上海新窝信息科技有限公司 一种健康监测方法及系统
CA3007606A1 (en) 2015-12-09 2017-06-15 Ramot At Tel-Aviv University Ltd. Method and system for sensing
JP2019526794A (ja) 2016-08-22 2019-09-19 ラモット・アット・テル・アビブ・ユニバーシテイ・リミテッドＲａｍｏｔ Ａｔ Ｔｅｌ Ａｖｉｖ Ｕｎｉｖｅｒｓｉｔｙ Ｌｔｄ． 生物検体の検出のための方法およびシステム
KR20190038660A (ko) 2016-08-22 2019-04-08 라모트 앳 텔-아비브 유니버시티 리미티드 피하 센싱을 위한 방법 및 시스템
US11619634B2 (en) * 2017-08-21 2023-04-04 Savicell Diagnostic Ltd. Methods of diagnosing and treating lung cancer
CN110491511B (zh) * 2019-07-24 2023-04-07 广州知汇云科技有限公司 一种基于围术期危险预警的多模型互补增强机器学习方法
IT202000016429A1 (it) * 2020-07-07 2022-01-07 Univ Degli Studi Udine Metodo per la valutazione dell’attivita’ metabolica di una cellula non-tumorale
WO2022109732A1 (en) * 2020-11-26 2022-06-02 12535441 Canada Ltd. Spectral diagnostic system
US20240358835A1 (en) * 2021-08-17 2024-10-31 Orgenesis Inc. Tumor infiltrating lymphocytes with increased metabolic activity

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US7713733B2 (en) * 2001-08-06 2010-05-11 Vanderbilt University Device and methods for detecting the response of a plurality of cells to at least one analyte of interest
JP4625946B2 (ja) * 2004-11-02 2011-02-02 国立大学法人 岡山大学 ｐＨ測定装置及びｐＨ測定方法
EP1736780A1 (en) 2005-06-24 2006-12-27 Eppendorf Array Technologies S.A. Method and means for detecting and/or quantifying hierarchical molecular change of a cell in response to an external stimulus
WO2008018905A2 (en) * 2006-01-17 2008-02-14 Cellumen, Inc. Method for predicting biological systems responses
CA2641954C (en) 2006-03-06 2016-04-26 Zetiq Technologies Ltd. Methods and compositions for identifying a cell phenotype
WO2011000572A1 (de) 2009-07-02 2011-01-06 Patenthandel Portfoliofonds I Gmbh & Co. Kg Verfahren und vorrichtung zum nachweis von biologischen langzeiteffekten in zellen
WO2011031803A1 (en) * 2009-09-08 2011-03-17 Nodality, Inc. Analysis of cell networks
CA2832031C (en) 2011-04-06 2019-09-17 Ramot At Tel-Aviv University Ltd. Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same

Also Published As

Publication number Publication date
US8728758B2 (en) 2014-05-20
US20180038849A1 (en) 2018-02-08
AU2012240953A1 (en) 2013-10-17
ES2627154T3 (es) 2017-07-26
WO2012137207A1 (en) 2012-10-11
CA2832031A1 (en) 2012-10-11
KR20140024871A (ko) 2014-03-03
US20130224789A1 (en) 2013-08-29
AU2012240953B2 (en) 2017-02-23
DK2694962T3 (en) 2017-06-12
KR102010600B1 (ko) 2019-08-13
CN103518133B (zh) 2016-08-17
JP2014512006A (ja) 2014-05-19
US9784731B2 (en) 2017-10-10
CN103518133A (zh) 2014-01-15
BR112013025782B1 (pt) 2022-09-06
EP2694962A1 (en) 2014-02-12
JP5990254B2 (ja) 2016-09-07
BR112013025782A2 (pt) 2016-12-20
US20140255972A1 (en) 2014-09-11
EP2694962B1 (en) 2017-03-01

Similar Documents

Publication Publication Date Title
CA2832031C (en) Methods of monitoring and analyzing metabolic activity profiles diagnostic and therapeutic uses of same
Meghraoui-Kheddar et al. Two new neutrophil subsets define a discriminating sepsis signature
Ferreira et al. Cells with Treg-specific FOXP3 demethylation but low CD25 are prevalent in autoimmunity
Oberbeck et al. Noncanonical effector functions of the T-memory–like T-PLL cell are shaped by cooperative TCL1A and TCR signaling
Zhang et al. Single-cell analysis highlights a population of Th17-polarized CD4+ naïve T cells showing IL6/JAK3/STAT3 activation in pediatric severe aplastic anemia
Caldeira et al. Immunophenotype of neutrophils in oral squamous cell carcinoma patients
Lee et al. Use of a platform with lens-free shadow imaging technology to monitor natural killer cell activity
Liu et al. Insights gained from single-cell analysis of immune cells in tofacitinib treatment of Vogt-Koyanagi-Harada disease
Baraniuk et al. Meta-analysis of natural killer cell cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome
Shi et al. CXCR6 defines therapeutic subtypes of CD4+ cytotoxic T cell lineage for adoptive cell transfer therapy in pediatric B cell acute lymphoblastic leukemia
Hwang et al. Monocyte subsets to differentiate chronic myelomonocytic leukemia from reactive monocytosis
Dutta et al. High baseline PD-1+ CD8 T Cells and TIGIT+ CD8 T Cells in circulation associated with response to PD-1 blockade in patients with non-small cell lung cancer
Rodriguez et al. Predictive nonlinear modeling of malignant myelopoiesis and tyrosine kinase inhibitor therapy
Tian et al. HLA‐DR+ mucosal‐associated invariant T cells predict poor prognosis in patients with sepsis: a prospective observational study
Singh et al. Decoding functional and developmental trajectories of tissue-resident uterine dendritic cells through integrative omics
EP3880838B1 (en) Compositions and methods of prognosis and classification for preeclampsia
Sánchez-Menéndez et al. Differences in the peripheral blood immune landscape between early-onset and late-onset colorectal cancer
Igase et al. The caninized anti-canine PD-1 monoclonal antibody in canine oral Malignant melanoma: Efficacy and exploratory biomarker analysis
US20260120879A1 (en) Machine learning technique for identifying ici responders and non-responders
Chen et al. Expression of regulatory T cells in driver-gene-negative advanced non-small cell lung cancer as well as its effect on the therapeutic efficacy and prognosis of immune checkpoint inhibitors
McGuire et al. Use of Mass Cytometry to Study Human Diseases involving the Immune System
Zhang et al. Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation
Gautam et al. Characterizing Mouse Platelet Heterogeneity Across Diverse Disease Models Using Spectral Flow Cytometry and High-Dimensional Analysis
Kim Dissection of Macrophage Diversity in Hepatocellular Carcinoma Elucidates Molecular Correlates to aPD-1 Response
Huang et al. Multi-omics Blueprint of Cellular Senescence in Deciphering Immune Characteristics and Prognosis Stratification of CRC

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170313

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250403

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250403

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260331

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260331